The University of Brighton is a UK university of over 21,000 students and 2,500 staff based on five campuses in Brighton, Eastbourne and Hastings on the south coast of England. Its roots can be traced back to 1859 when the Brighton School of Art was opened in the Brighton Royal Pavilion.The university focuses on professional education, with the majority of degrees awarded also leading to professional qualifications in areas including Pharmacy, Engineering and Information Technology.In 2012 the University of Brighton came third in the People & Planet's Green League table of UK universities ranked by environmental and ethical performance. Wikipedia.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: DS-06-2014 | Award Amount: 3.55M | Year: 2015
Despite the importance of Critical Information Infrastructures (CIIs) and dynamic ICT-based maritime supply chains (SCs) for port operations, state-of-the-art Risk Management (RM) methodologies for maritime environments pay limited attention to cyber-security and do not adequately address security processes for international SCs. Motivated by these limitations, MITIGATE will introduce, integrate, validate and commercialize a novel RM system, which will empower stakeholders collaboration for the identification, assessment and mitigation of risks associated with cyber-security assets and SC processes. This collaborative system will boost transparency in risk handling, while enabling the generation of unique evidence about risk assessment and mitigation. At the heart of the RM system will be an open simulation environment enabling stakeholders to simulate risks and evaluate risk mitigation actions. This environment will allow users to model, design, execute and analyze attack-oriented simulations. Emphasis will be paid on the estimation of cascading effects in SCs, as well as on the prediction of future risks. MITIGATE will be compliant with prominent security standards and regulations for the maritime sector (i.e. ISO27000, ISO28000, ISPS). The MITIGATE system will be built based on readily available technologies of the partners, which will enable the project to produce a mature (high-TRL) system at an optimal value-for-money. The system will be validated based on real-life pilot operations across five EU ports (Bremen, Piraeus, Valencia, Ravenna, Livorno) with the active participation of over 500 users (security officers, terminal operators, facility operators, standardization experts and more). Also, the projects approach will be contributed as a blueprint to the NIS public-private platform. Finally, significant effort will be devoted to the commercialization of the MITIGATE system based on pragmatic business plans and market launch actions.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: INNOSUP-7-2015 | Award Amount: 1.69M | Year: 2016
Current research and practice on Open Innovation (OI) has not given emphasis on the ability of SMEs to develop and implement OI strategies - the lessons learned from large firms are not readily transferable to their context. INSPIRE aims to thoroughly investigate how OI is managed and organised in SMEs in order to leverage and expand the existing scattered initiatives and professionalize their services. The project seeks to understand in depth good practices of OI in SMEs across Europe, including the barriers they experience, the critical success factors and the open innovation pathways they follow. Good practices will be identified in all varieties of SMEs in terms of economic context, innovation trajectory (e.g. both high-tech and low-tech SMEs) and stage of lifetime. The understanding of good practices will allow the design, development and validation of an Integrated Toolbox for OI in SMEs to enable the professional management of OI by SMEs in various kinds of open innovation initiatives (e.g. facilitated by large corporations, private-public partnerships). The Toolbox will include good practices, indicators and management modules to support the internal innovation activities of an SME and their interaction with OI partners. The Toolbox will be modular and it will include three prototypical scenarios of usage that can be flexibly adjusted to individual needs of SMEs. The Integrated Toolbox will be developed as a web platform and it will be validated through a series of pilots in real life OI projects carried out by SMEs across Europe. Moreover, the project will develop a deployment plan for the Open Innovation System to initiate an EU-wide strategic engagement of innovation stakeholders and spread the practices of OI. The consortium includes a variety of competencies to access the whole Open Innovation chain across a range of geographical, economic and SMEs contexts and includes academics, practitioners and intermediaries working with SMEs on Open Innovation.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-14-2014 | Award Amount: 8.21M | Year: 2015
SESAME targets innovations around three central elements in 5G: the placement of network intelligence and applications in the network edge through Network Functions Virtualisation (NFV) and Edge Cloud Computing; the substantial evolution of the Small Cell concept, already mainstream in 4G but expected to deliver its full potential in the challenging high dense 5G scenarios; and the consolidation of multi-tenancy in communications infrastructures, allowing several operators/service providers to engage in new sharing models of both access capacity and edge computing capabilities. SESAME proposes the Cloud-Enabled Small Cell (CESC) concept, a new multi-operator enabled Small Cell that integrates a virtualised execution platform (i.e., the Light DC) for deploying Virtual Network Functions (NVFs), supporting powerful self-x management and executing novel applications and services inside the access network infrastructure. The Light DC will feature low-power processors and hardware accelerators for time critical operations and will build a high manageable clustered edge computing infrastructure. This approach will allow new stakeholders to dynamically enter the value chain by acting as host-neutral providers in high traffic areas where densification of multiple networks is not practical. The optimal management of a CESC deployment is a key challenge of SESAME, for which new orchestration, NFV management, virtualisation of management views per tenant, self-x features and radio access management techniques will be developed. After designing, specifying and developing the architecture and all the involved CESC modules, SESAME will culminate with a prototype with all functionalities for proving the concept in relevant use cases. Besides, CESC will be formulated consistently and synergistically with other 5G-PPP components through coordination with the corresponding projects.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-13-2014 | Award Amount: 6.23M | Year: 2015
Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around 15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment. Gut-derived endotoxins and bacterial translocation are central factors implicated in the pathogenesis of fatty liver disease and, the development and progression of cirrhosis. In cirrhosis, current state-of-the-art therapy to prevent recurrent complications of advanced cirrhosis is to use poorly absorbed antibiotics but long-term antibiotic therapy has problems associated with bacterial resistance, infection with resistant organisms and the cost. Treatment of fatty liver and modulation of bacterial translocation in early cirrhosis to prevent complications is an unmet need. Our academic-industrial consortium has developed a novel, patented, safe and cheap nanoporous carbon that modulates the effects of bacterial translocation in animal models of liver disease. Our feasibility studies demonstrate that this product advances the current state-of-the-art, is a TRL 4/5 and is now ready for validation through clinical trials. We propose to investigate the safety and efficacy of this novel nanoporous carbon in patients with fatty liver disease and cirrhosis. If successful, we will be able to confirm an innovative, cost-effective and novel strategy for the management of this chronic disease in a European population. Exploitation of the results of the CARBALIVE project will support the continued development of this carbon through additional private and public sector investment. The use of this innovative therapy is expected to reduce the economic burden of the disease in Europe, allow patients to achieve enhanced quality of life, improve survival, and allow many patients to return to economic productivity.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-26-2014 | Award Amount: 5.46M | Year: 2015
EmERGE will develop a mHealth platform to enable self-management of HIV in patients with stable disease. The platform will build upon and integrate the existing mHealth solutions operated by pioneering healthcare providers in the UK and Spain and apply a rigorous co-design approach to ensure patient and clinician input to the solution. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to key healthcare providers EATG, the European HIV patient organisation, will provide a direct and deep interaction with representative patients and clinicians from 5 EU countries. The platform and interfaces will be validated in a large study of 3900 patients using a tailored HTA process, MAST, specifically developed for the assessment of mHealth solutions including translatability as a key factor. Based on prior work showing a high uptake rate and use of mHealth in HIV patient populations, EmERGE aims to demonstrate the benefits to patients and simultaneous increases in cost-effectiveness for healthcare providers by reducing face-to-face consultations, estimated at 6000 saved per year within this study alone. Patient reported outcomes will be agreed and used in the assessment and development of the system which also aims to increase adherence and enable frailty to be reported using mHealth technology. Innovation will be given priority from the beginning by developing new business models of care provision, targeting key stakeholders in the EU health provider sector, including policymakers and clinicians, while eliciting demand from patients to highlight and initiate the widespread implementation and compensation of mHealth solutions within the timeframe of the project. Guidelines and policy briefs will be produced to evidence the benefits and disseminate the lessons learned to support the uptake of mHealth for self-management of other chronic diseases.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-03-2016 | Award Amount: 3.89M | Year: 2017
MADIA aims at realizing a versatile and cheap diagnostic device based on magnetoresistive sensors, microfluidic device, ultrasmall Magnetic Nanoparticles (MNPs) and advanced bio-chemical functionalization methods for the early and ultrasensitive in vitro detection of biomarkers trustfully associated with 2 incurable neurodegenerative diseases: Alzheimers Disease (AD) and Parkinson Disease (PD). We plan to achieve sensitivities at least three orders of magnitude higher than best state-of-the-art values flexibility to operate for a wide range of concentrations. WHY: Neurodegenerative diseases (ND) are debilitating and largely untreatable conditions that are strongly linked with age. Amongst these disorders, the dementias are responsible for the greatest burden of disease, with Alzheimers disease and related disorders affecting some 7 million people in Europe. The current costs of the order of 130 billion per annum to care for people with dementia across Europe highlight age-related neurodegenerative disease as one of the largest medical and societal challenges faced by our society. PD is the second most common neurodegenerative disorder worldwide after AD. WHAT: The operation principle behind the proposed tool embodies a Magnetic Sensor Assay approach and consists of recognizing the targeted core and downstream biomarkers obtained from body fluids (such as cerebrospinal fluid - CSF and blood) through their complexation with nano-magnetic labels (MNPs) followed by a highly sensitive magnetic detection at micro-scales. The specific recognition of the protein by the magnetic nanoparticles will be achieved and ensured via protein bonding to functionalizing groups grafted on the surface of the MNP. The complexes MNP-BM will be injected into microfluidics channels flowing in the close vicinity of magnetic sensors, bringing thus the MNP-BM to distances where the magnetic field of the MNP will trigger a quantitatively detectable sensor response.